|
Name |
yanuthone D
|
Molecular Formula | C28H38O8 | |
IUPAC Name* |
5-[[(1S)-2,5-dioxo-6-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid
|
|
SMILES |
CC(=CCC/C(=C/CC/C(=C/CC12[C@H](O1)C(=O)C(=CC2=O)COC(=O)CC(C)(CC(=O)O)O)/C)/C)C
|
|
InChI |
InChI=1S/C28H38O8/c1-18(2)8-6-9-19(3)10-7-11-20(4)12-13-28-22(29)14-21(25(33)26(28)36-28)17-35-24(32)16-27(5,34)15-23(30)31/h8,10,12,14,26,34H,6-7,9,11,13,15-17H2,1-5H3,(H,30,31)/b19-10+,20-12+/t26-,27?,28?/m1/s1
|
|
InChIKey |
NIBXHVDVUJEQPO-OFWAVEGMSA-N
|
|
Synonyms |
yanuthone D
|
|
CAS | NA | |
PubChem CID | 139586902 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 502.6 | ALogp: | 3.8 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 131.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 36 | QED Weighted: | 0.198 |
Caco-2 Permeability: | -5.358 | MDCK Permeability: | 0.00001540 |
Pgp-inhibitor: | 0.065 | Pgp-substrate: | 0.842 |
Human Intestinal Absorption (HIA): | 0.314 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.025 |
Blood-Brain-Barrier Penetration (BBB): | 0.022 | Plasma Protein Binding (PPB): | 83.61% |
Volume Distribution (VD): | 0.375 | Fu: | 11.81% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.065 |
CYP2C19-inhibitor: | 0.067 | CYP2C19-substrate: | 0.172 |
CYP2C9-inhibitor: | 0.189 | CYP2C9-substrate: | 0.962 |
CYP2D6-inhibitor: | 0.027 | CYP2D6-substrate: | 0.041 |
CYP3A4-inhibitor: | 0.183 | CYP3A4-substrate: | 0.165 |
Clearance (CL): | 7.353 | Half-life (T1/2): | 0.72 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.655 |
Drug-inuced Liver Injury (DILI): | 0.623 | AMES Toxicity: | 0.826 |
Rat Oral Acute Toxicity: | 0.019 | Maximum Recommended Daily Dose: | 0.227 |
Skin Sensitization: | 0.926 | Carcinogencity: | 0.221 |
Eye Corrosion: | 0.106 | Eye Irritation: | 0.048 |
Respiratory Toxicity: | 0.939 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003133 | 0.743 | D09XWD | 0.397 | ||||
ENC001464 | 0.423 | D05XQE | 0.389 | ||||
ENC006119 | 0.410 | D03VFL | 0.367 | ||||
ENC001465 | 0.410 | D01ZUA | 0.239 | ||||
ENC001466 | 0.410 | D06BLQ | 0.219 | ||||
ENC001716 | 0.404 | D09ANG | 0.204 | ||||
ENC001096 | 0.386 | D0X7XG | 0.202 | ||||
ENC001462 | 0.386 | D0ZI4H | 0.197 | ||||
ENC004068 | 0.374 | D04FBR | 0.187 | ||||
ENC003494 | 0.364 | D03JSJ | 0.184 |